CRWV
CoreWeave, Inc. Class A Common Stock
CRWV's outlook is improving, though it still trails on the overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over CRWV overall, supported by lower modeled downside and stronger fundamentals.
CRWV Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
CRWV's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CRWV PE Valuation
CRWV has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CRWV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Low |
CRWV has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CRWV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.31 | -$1.83 |
| Q2 2026 | -$3.26 | -$0.16 |
| Q1 2026 | -$2.72 | +$0.62 |
| Q4 2025 | -$2.81 | -$0.64 |
| Q3 2025 | -$2.48 | -$0.06 |
CRWV lost $4.31 per share over the past year, a bigger loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CRWV on earnings quality, reporting a profit while its opponent remains loss making.
CRWV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +168% |
| Q2 2026 | $2.6B | +112% |
| Q1 2026 | $2.1B | +112% |
| Q4 2025 | $1.6B | +110% |
| Q3 2025 | $1.4B | +134% |
| Q2 2025 | $1.2B | +207% |
| Q1 2025 | $981.6M | +420% |
| Q4 2024 | $747.4M | +544% |
CRWV has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | +1.9 points |
| Q2 2026 | -1.9% | -3.5 points |
| Q1 2026 | -6.9% | -4.1 points |
| Q4 2025 | -5.7% | -21 points |
| Q3 2025 | 3.8% | -16 points |
| Q2 2025 | 1.6% | -18 points |
| Q1 2025 | -2.8% | -12 points |
| Q4 2024 | 15% | +17 points |
CRWV's operating margin was 5.7% last quarter, up 1.9 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CRWV on profitability, with a higher operating margin.
CRWV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.5B | -$6.8B |
| Q2 2026 | -$5.7B | -$3B |
| Q1 2026 | -$4.7B | -$3.4B |
| Q4 2025 | -$2.5B | +$810.3M |
| Q3 2025 | -$699.8M | -$125.8M |
| Q2 2025 | -$2.7B | -$339.3M |
| Q1 2025 | -$1.3B | -553% |
| Q4 2024 | -$3.3B | -$2.2B |
CRWV has burned cash in almost every quarter: −$20.4B over the past year, against −$8.1B the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CRWV on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRWV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +8M shares |
| 1 year | +12% | +61.1M shares |
CRWV has 559M diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | $1.5M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | $32.1M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CRWV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CRWV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | -1.5x | Net Cash |
| Q1 2026 | 7.6x | High |
| Q4 2025 | 7.6x | High |
| Q3 2025 | 5.6x | High |
| Q2 2025 | 6.5x | High |
| Q1 2025 | 8.4x | High |
| Q4 2024 | 19.3x | High |
CRWV has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CRWV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.7 | Neutral |
| Stochastic | 11.3 | Oversold |
CRWV's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CRWV PE vs Technology Sector
CRWV has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CRWV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $66.6 | 15% below |
| 20 week MA | $77.4 | 27% below |
| 50 week MA | $87.4 | 35% below |
UNH has stronger trend alignment. CRWV is above 0 of 3 weekly averages versus UNH above 4 of 5.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
CRWV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $40.0 | $76.4 | +91% |
| 2026 YTD | $76.4 | $56.6 | -26% |
CRWV has finished every year since 2025 higher, and it's down 26% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CRWV on returns for 2026, with the stronger performance.